Menopausal hormone therapy: a better and safer future.

Major advances in menopause hormone therapy (MHT) hold promise in the future of better and safer care for women at and after the menopause. The principal advances are: (1) the critical window or 'window of opportunity' in the 10 years or so after the menopause, during which the benefits of MHT in healthy women exceed any risks; (2) use of transdermal instead of oral administration of estrogen to reduce the risk of venous thromboembolism; (c) investigation of the use of oral micronized progesterone (MP) and vaginal MP to prevent endometrial hyperplasia and carcinoma without any increased risk of breast cancer and venous thromboembolism in postmenopausal women receiving estrogens; vaginal MP prevents endometrial proliferation in the short term but the long-term effects in MHT remain to be established; (4) investigation into the use of intrauterine levonorgestrel-releasing devices (LNG-IUDs), which are an attractive form of MHT in perimenopausal women, providing contraception and reducing uterine bleeding, although the risk of breast cancer with LNG-IUDs requires clarification. Women in the future can look forward to a symptom-free menopause and to safer and more beneficial MHT.

The Peninsula Maternity and Neonatal Service. An urban community perinatal programme.

The first year of existence of the Peninsula Maternity and Neonatal Service (PMNS) is reviewed. Some 21000 deliveries per annum fall under the Service. The ethnic distribution in 1980 was 27% Black, 69% Coloured and 4% White. The perinatal mortality rates per 1000 births were 31,2 for Blacks, 29,4 for Coloureds and 15,0 for Whites, with an overall perinatal mortality rate for the PMNS of 29,2. The administration of the PMNS is described. The Midwife Obstetric Units are discussed under the following headings: function, workload, advantages, and continuing education. Research opportunities and the main problems in the PMNS are outlined.